octapharma
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Treatment of haemophilia A with FVIII replacement has evolved over the past decades to adapt to the needs of patients. octanate…
DISCLOSURES
Montegaard: Pharmacyclics: Consultancy; Janssen: Consultancy. Jacobson:Kite, a Gilead Company: Consultancy, Honoraria…
Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product…
Introduction: Hemophilia is a bleeding disorder characterized by ineffective clot formation due to insufficient thrombin…
Abstract We present 25-year experience with inhibitors in previously untreated patients (PUPs) with severe hemophilia A in…
Among adults undergoing non‐cardiac surgery who are at risk of a myocardial infarction, a long‐standing question has been whether…
Patients with haemophilia A (and their physicians) may be reluctant to switch factor VIII (FVIII) concentrates, often due to…
Introduction: Antiepileptic drug (AED) teratogenicity is suspected to be the main cause of impaired development in children of…
Emergency stroke care has become a natural part of the emerging discipline of neurocritical care and demands close cooperation…